Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis
Abstract
Background:
Monitoring neuronal injury remains one key challenge in early relapsing-remitting multiple sclerosis (RRMS) patients. Upon axonal damage, neurofilament – a major component of the neuro-axonal cytoskeleton – is released into the cerebrospinal fluid (CSF) and subsequently peripheral blood.
Objective:
To investigate the relevance of serum neurofilament light chain (sNfL) for acute and chronic axonal damage in early RRMS.
Methods:
sNfL levels were determined in 74 patients (63 therapy-naive) with recently diagnosed clinically isolated syndrome (CIS) or RRMS using Single Molecule Array technology. Standardized 3 T magnetic resonance imaging (MRI) was performed at baseline and 1–3 consecutive follow-ups (42 patients; range: 6–37 months).
Results:
Baseline sNfL correlated significantly with T2 lesion volume (r = 0.555, p < 0.0001). There was no correlation between baseline sNfL and age, Expanded Disability Status Scale (EDSS) score or other calculated MRI measures. However, T2 lesion volume increased (r = 0.67, p < 0.0001) and brain parenchymal volume decreased more rapidly in patients with higher baseline sNfL (r = −0.623, p = 0.0004). Gd-enhancing lesions correlated positively with sNfL levels. Initiation of disease-modifying treatment led to a significant decrease in sNfL levels.
Conclusion:
sNfL indicates acute inflammation as demonstrated by correlation with Gd+ lesions. It is a promising biomarker for neuro-axonal damage in early multiple sclerosis (MS) patients, since higher baseline sNfL levels predicted future brain atrophy within 2 years.
Get full access to this article
View all access and purchase options for this article.
References
1. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552–556.
2. Gracien RM, Reitz SC, Hof SM, et al. Longitudinal quantitative MRI assessment of cortical damage in multiple sclerosis: A pilot study. J Magn Reson Imaging 2017; 46: 1485–1490.
3. Haider L, Zrzavy T, Hametner S, et al. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain 2016; 139: 807–815.
4. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.
5. Malmestrom C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720–1725.
6. Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016; 54: 1655–1661.
7. Kuhle J, Barro C, Disanto G, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler 2016; 22: 1550–1559.
8. Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81: 857–870.
9. Cortes C, Vapnik V. Support-vector networks. Mach Learn 1995; 20: 273–297.
10. Londono AC, Mora CA. Evidence of disease control: A realistic concept beyond NEDA in the treatment of multiple sclerosis. F1000Res 2017; 6: 566.
11. Larochelle C, Uphaus T, Prat A, et al. Secondary progression in multiple sclerosis: Neuronal exhaustion or distinct pathology? Trends Neurosci 2016; 39: 325–339.
12. Sartori A, Abdoli M, Freedman MS. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. J Neurol 2017; 264: 1068–1075.
13. Kuhle J, Nourbakhsh B, Grant D, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 2017; 88: 826–831.
14. Bevan CJ, Cree BA. Disease activity free status: A new end point for a new era in multiple sclerosis clinical research? JAMA Neurol 2014; 71: 269–270.
15. Giovannoni G, Tomic D, Bright JR, et al. ‘No evident disease activity’: The use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 2017; 23: 1179–1187.
16. Cree BA, Gourraud PA, Oksenberg JR, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016; 80: 499–510.
17. Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83–89.
18. Kuhle J, Disanto G, Lorscheider J, et al. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84: 1639–1643.
19. de Flon P, Gunnarsson M, Laurell K, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 2016; 87: 141–147.
20. Piehl F, Kockum I, Khademi M, et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler 2018; 24: 1046–1054.
Supplementary Material
Supplemental material files:
File (msj765666_supplementary_figure_1.pdf)
- Download
- 326.83 KB
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: March 15, 2018
Issue published: April 2019
Keywords
PubMed: 29542376
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 2810
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 128 view articles Opens in new tab
Crossref: 136
- Recent Advances in Diagnostic, Prognostic, and Disease-Monitoring Biom...
- Serum and cerebrospinal fluid neurofilament light chains measured by S...
- The consequences of delayed diagnosis and treatment in persons with mu...
- Studying serum neurofilament light chain levels as a potential new bio...
- Proteomics reveal biomarkers for diagnosis, disease activity and long-...
- Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A...
- N-acetylglucosamine inhibits inflammation and neurodegeneration marker...
- MRI graph parameters are longitudinal markers of neuronal integrity in...
- Cerebrospinal fluid neurofilament light chains predicts early disease-...
- Accuracy of serum neurofilament light to identify contrast-enhancing l...
- Serum neurofilament light chain is more strongly associated with T2 le...
- A cross‐sectional study of ageing at the mouse neuromuscular junction ...
- Insight into Early Diagnosis of Multiple Sclerosis by Targeting Progno...
- Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disea...
- Biomarkers in autoimmune diseases of the central nervous system
- Validity of serum neurofilament light chain as a prognostic biomarker ...
- Neurofilament light chains in serum as biomarkers of axonal damage in ...
- Recent Progress in the Identification of Early Transition Biomarkers f...
- Evaluation of cerebrospinal fluid ubiquitin C-terminal hydrolase-L1, g...
- Sección I: Diagnóstico de la esclerosis múltiple capítulo 3Bandas olig...
- Serum Neurofilament Identifies Patients With Multiple Sclerosis With S...
- Plasma Neurofilament Light Chain Is Elevated after Transcatheter Aorti...
- Distribution of five clinically important neuroglial proteins in the h...
- Biofabrication of Multiplexed Electrochemical Immunosensors for Simult...
- Minocycline treatment in clinically isolated syndrome and serum NfL, G...
- Associations between neurofilament light chain levels, disease activit...
- A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
- An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Scler...
- Progressive Multiple Sclerosis
- Multidimensional overview of neurofilament light chain contribution to...
- Serum Neurofilament Light Chain in Patients With Atrial Fibrillation
- Improved prediction of early cognitive impairment in multiple sclerosi...
- NFL during acute spinal cord lesions in MS: a hurdle for the detection...
- Prospectively assessing serum neurofilament light chain levels as a bi...
- Blood Neurofilament Light in Progressive Multiple Sclerosis
- Differential diagnosis of demyelinating diseases: what's new?
- Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis
- Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment...
- Prognostic Value of Serum Neurofilament Light Chain for Disease Activi...
- Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and B...
- Neurodegeneration and convergent factors contributing to the deteriora...
- Charting a global research strategy for progressive MS—An internationa...
- Laboratory biomarkers of Multiple Sclerosis (MS)
- Impact of Dietary Intervention on Serum Neurofilament Light Chain in M...
- Low serum neurofilament light chain values identify optimal responders...
- The potential of serum neurofilament as biomarker for multiple scleros...
- Plasma neurofilament light chain levels are predictors of disease acti...
- Cerebrospinal Tau levels as a predictor of early disability in multipl...
- Serum GFAP and NfL levels in benign relapsing-remitting multiple scler...
- NfL predicts relapse-free progression in a longitudinal multiple scler...
- Neurofilament light chain and disease activity in patients with multip...
- The blood biomarkers puzzle – A review of protein biomarkers in neurod...
- Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexi...
- Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Dama...
- Disease biomarkers in multiple sclerosis: current serum neurofilament ...
- Effect of Eight –Weeks of Resistance Training on Serum Levels of Neuro...
- The diagnostic and prognostic capabilities of plasma biomarkers in Alz...
- Neurofilament light chain as a biomarker of meningoencephalitis of unk...
- Identification of patients with relapsing multiple sclerosis eligible ...
- Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progressio...
- Predicting disability worsening in relapsing and progressive multiple ...
- Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the ...
- The Evolution of Neurofilament Light Chain in Multiple Sclerosis
- GAMER-MRI in Multiple Sclerosis Identifies the Diffusion-Based Microst...
- Integrative biochemical, proteomics and metabolomics cerebrospinal flu...
- Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Ar...
- Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical...
- Involvement of cytotoxic Eomes-expressing CD4 + ...
- Neurofilament light chain levels reflect outcome in a patient with glu...
- Serum neurofilament light chain reflects inflammation-driven neurodege...
- Implications of extreme serum neurofilament light chain levels for the...
- Serum neurofilament levels reflect outer retinal layer changes in mult...
- Association of serum neurofilament light chain levels and neuropsychia...
- Translational Value of CSF and Blood Markers of Autoimmunity and Neuro...
- Herpesviruses and biomarkers in disseminated encephalomyelitis and mul...
- Neurofilament Light Chain Levels Are Associated with Disease Activity ...
- High serum neurofilament associates with diffuse white matter damage i...
- Serum neurofilament light chain predicts long term clinical outcomes i...
- Serum GFAP in multiple sclerosis: correlation with disease type and MR...
- Blood neurofilament light: a critical review of its application to neu...
- Association of Serum Neurofilament Light Levels With Long-term Brain A...
- The weak association between neurofilament levels at multiple sclerosi...
- Blood Neurofilament Light Chain: The Neurologist’s Troponin?
- Toward allele-specific targeting therapy and pharmacodynamic marker fo...
- Serum neurofilament-light concentration and real-world outcome in MS
- Apolipoproteins AI and E are associated with neuroaxonal injury to gra...
- Evolution of Cortical and White Matter Lesion Load in Early-Stage Mult...
- Long-term prognostic value of longitudinal measurements of blood neuro...
- Elevated serum neurofilament light chain in children autism spectrum d...
- Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients...
- Current state-of-art of the application of serum neurofilaments in mul...
- Novel decision algorithm to discriminate parkinsonism with combined bl...
- Neurofilaments: neurobiological foundations for biomarker applications
- Serum neurofilament light chain is a useful biomarker in pediatric mul...
- Plasma neurofilament light levels are associated with risk of disabili...
- Clinical implications of serum neurofilament in newly diagnosed MS pat...
- Temporal association of sNfL and gad‐enhancing lesions in multiple scl...
- Systematic review of prediction models in relapsing remitting multiple...
- Longitudinal analysis of serum neurofilament light chain: A potential ...
- Serum Neurofilament Light Predicts Severity and Prognosis in Patients ...
- Neurofilaments in disease: what do we know?
- Serum glial fibrillary acidic protein correlates with multiple scleros...
- Response by Uphaus et al to Letter Regarding Article, “NfL (Neurofilam...
- Characterization of TAG‐63 and its role on axonal transport in ...
- Multiple Sclerosis
- Neurofilament Light Chain as a Biomarker, and Correlation with Magneti...
- Plasma neurofilaments correlate with disability in progressive multipl...
- Neurofilaments: The C-Reactive Protein of Neurology
- Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value ...
- NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long...
- AD biomarker discovery in CSF and in alternative matrices
- Serum GFAP and neurofilament light as biomarkers of disease activity a...
- Serum neurofilament light chain in pediatric MS and other acquired dem...
- Neurofilament levels in patients with neurological diseases: A compari...
- The β‐secretase (BACE) inhibitor NB‐360 in preclinical models: From am...
- Intrathecal B-cell accumulation and axonal damage distinguish MRI-base...
- Plasma Lipid Profiling Identifies Biomarkers of Cerebral Microvascular...
- Implementing the 2017 McDonald criteria for the diagnosis of multiple ...
- Establishment of neurofilament light chain Simoa assay in cerebrospina...
- Serum and CSF neurofilament light chain levels in antibody-mediated en...
- High-density lipoprotein cholesterol is associated with multiple scler...
- CSF parameters associated with early MRI activity in patients with MS
- Neurofilament light chain in the assessment of patients with multiple ...
- Blood neurofilament light as a potential endpoint in Phase 2 studies i...
- Reaching an evidence-based prognosis for personalized treatment of mul...
- Profiling individual clinical responses by high-frequency serum neurof...
- Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
- Serum NFL discriminates Parkinson disease from atypical parkinsonisms
- Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegen...
- Vitamin D Supplementation as Add-on Therapy in Multiple Sclerosis—Bala...
- Serum neurofilament light and prediction of multiple sclerosis in clin...
- Acid sphingomyelinase: No potential as a biomarker for multiple sclero...
- Retinal measurements predict 10‐year disability in multiple sclerosis
- Multiple sclerosis
- Studying the blood–brain barrier will provide new insights into neurod...
- AAN unveils new guidelines for MS disease-modifying therapy
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
